GEO DataSet Links for BioProject (Select 149157) - GEO DataSets

Warning: The NCBI web site requires JavaScript to function. more...

Format

Summary
Summary (text)
Unique Identifier List

Sort by

Default order
Number of Samples (High to Low)
Number of Samples (Low to High)

Send to:

Choose Destination

File
Clipboard
Collections

Links from BioProject

Items: 2

Select item 2000332231.

Multilineage dysplasia does not influence prognosis in patients with CEBPA mutated AML supporting the WHO proposal to classify these patients as a unique entity

(Submitter supplied) By WHO 2008, CEBPA-mutated AML became a provisional subentity, but it remains to be clarified how CEBPAmut AML with multilineage dysplasia (MLD; ≥50% dysplastic cells in 2-3 lineages) but no other MDS-related feature should be classified. We investigated 108 CEBPAmut AML (15.7-87.6 years) for the impact of MLD and genetic features. MLD-positive patients differed from MLD-negative only by lower mean WBC counts (p=0.004), but not by other blood values, biologic characteristics, cytogenetic risk profiles, or additional molecular markers (NPM1mut, FLT3-ITD/TKD, RUNX1, MLL-PTD, IDH1/2). more...

Organism:: Homo sapiens

Type:: Expression profiling by array

Dataset:: GDS4407
Platform:: GPL570
30 Samples

Download data: CEL

Series

Accession:: GSE33223

ID:: 200033223

Select item 44072.

Biallelic CEBPA-mutated acute myeloid leukemia with multilineage dysplasia: peripheral blood mononuclear cells

Analysis of PBMCs from biallelic CEBPA (encoding CCAAT/enhancer binding protein)-mutated, acute myeloid leukemia (AML) patients with or without multilineage dysplasia (MLD). Cases without CEBPA mutations also examined. Results provide insight into the classification of CEBPA-mutated AML patients.